Stock Analysis of Biocardia Inc (BCDA) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code BCDA
Close 0.400
Change 0.0039 / 0.985 %
Volume 91182.00
Vol Change 23282.00 / 34.29 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthMild Bullish
Growth Index Poor Growth Stock
Value Index Poor Value Stock
Profitability Index Poor Profitability Stock
Stability Index Poor Stability Stock


Fundamental View of Biocardia Inc
PE (TTM)

-363.27

Very Poor
Price / Book

3409.60

Very Poor
Price / Sales

8812.06

Very Poor
Piotroski F Score

2.0

Poor
Market Cap

10744.31 K

Enterprise Value

9974.31 K

ROA (TTM)

-192.57

Very Poor
ROE (TTM)

-938.60

Very Poor
Net Margin (TTM)

-2425.79

Very Poor
Revenue

64.72 %

477000
Net Profit

2.82 %

-11571.00 K
Debt to Equity

-0.208

Very Poor
Altman Z Score

-83.86

Very Poor
Quick Ratio

0

Poor
Cash Ratio

0.306

Poor


Highs/Lows of Biocardia Inc
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week0.394 1.50 % 2.32 % 0.410.3809-May-2409-May-24
Two Week0.3762 6.30 % 5.77 % 0.410.370109-May-2402-May-24
One Month0.3736 7.04 % 4.87 % 0.410.3209-May-2422-Apr-24
Three Month0.43 7.00 % 5.54 % 0.590.3204-Mar-2422-Apr-24
Six Months0.945 57.68 % 17.88 % 0.960.3216-Nov-2322-Apr-24
One year1.85 78.38 % 28.33 % 2.91990.3221-Jun-2322-Apr-24
Two year1.4 71.44 % 31.92 % 2.91990.3221-Jun-2322-Apr-24
Five year9.0 95.56 % 86.19 % 2.91990.3221-Jun-2322-Apr-24
Ten year8.91 95.51 % 183.73 % 138.240.3229-Dec-1622-Apr-24


Technical View of Biocardia Inc
RSI

55.52

Neutral
MACD

0.0012

Strong Bullish
ADX

13.54

Neutral
Super Trend

0.416

Mild Bearish
Williams %R

-24.63

Neutral
CCI

102.64

Mild Bearish


EMA 5

0.396

Bullish
EMA 15

0.389

Bullish
EMA 50

0.404

Mild Bearish
EMA 100

0.468

Mild Bearish
SMA 100

0.457

Mild Bearish
SMA 200

0.525

Mild Bearish
SMA 5 / 20

0.397 / 0.382

Mild Bullish
SMA 15 / 50

0.385 / 0.391

Mild Bearish
SMA 50 / 200

0.391 / 0.525

Mild Bearish




Charts of Biocardia Inc


Returns of Biocardia Inc with Peers
Period / StockBCDAMDNAAVTXCMAX
1 Week1.50%-39.59%-11.42%-15.06%
1 Mth7.04%-46.76%-31.82%-13.23%
3 Mth-7.00%-65.82%118.28%-36.34%
6mth-57.68%-77.25%-56.18%-91.34%
1 Year-78.38%-78.55%-98.43%-96.34%
2 Year-71.44%-92.99%-98.56%-97.91%
5 Years-95.56%-84.74%-99.93%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Biocardia Inc with Peers
Ratio / StockBCDAMDNAAVTXCMAX
PE-363.27-0.777-0.091-4.10
P/B3409.600.372-6.707.47
ROA-192.57-39.88-109.45-70.93
ROE-938.60-47.880-182.04
Debt To Equity-0.20800.0746.43
Revenue477000
64.72 % 		0
% 		2249.00 K
87.54 % 		763530 K
20.98 %
Net Income-11571.00 K
2.82 % 		1547.00 K
106.83 % 		-33188.00 K
20.33 % 		-207147.00 K
169.45 %


Technicals of Biocardia Inc with Peers
Technical / StockBCDAMDNAAVTXCMAX-
ADX13.5435.3425.2910.07
CMF-0.357-0.088-0.253-0.380
MFI40.8515.4337.8540.78
RSI55.5216.5538.8140.69
MACD Abv SignalTrueFalseFalseTrue
Price Above 50 MATrueFalseFalseFalse-
Price Above 200 MAFalseFalseFalseFalse-


About : Biocardia Inc

Address : 320 Soquel Way, Sunnyvale, CA, United States, 94085
Tel : 650 226 0120
URL : https://www.biocardia.com
Code : BCDA, ISIN : US09060U5074, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 14_Mar_2008
Employee Count : 16

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California.


Note : All Data Generated at the End of Trading Hours (EOD Data)